VEGFA and neoplasm: Dynamic contrast-enhanced MRI (DCE-MRI) has been used as a biomarker to evaluate VEGF inhibitors (vascular endothelial growth factor) based on change in tumour vascular permeability as measured by the leakage of contrast media from the tumour vessels into the interstitial space and expressed as Ktrans.